Nitric oxide: a drug target for glaucoma revisited

Gerhard Garhöfer; Leopold Schmetterer

doi:10.1016/j.drudis.2019.05.033

Nitric oxide: a drug target for glaucoma revisited

Gerhard Garhöfer^*, Leopold Schmetterer

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

33 Citations (Scopus)

Abstract

A reduction in intraocular pressure (IOP) is the only recognized therapy for glaucoma. Hence, drugs exhibiting ocular hypotensive effects are important targets for antiglaucomatous drug development. IOP is determined by the equilibrium of aqueous humor production and outflow through either the trabecular meshwork or the uveoscleral outflow pathway. There is increasing evidence that nitric oxide (NO) has a major role in the regulation of IOP by directly acting on the trabecular meshwork and thereby lowering IOP. Taking advantage of this mechanism, newly designed NO-donating drugs combine the IOP-lowering effect of known substances with the trabecular meshwork outflow-increasing effect of NO. Here, we review the molecular mechanism of this new entity of IOP-lowering drugs.

Original language	English
Pages (from-to)	1614-1620
Number of pages	7
Journal	Drug Discovery Today
Volume	24
Issue number	8
DOIs	https://doi.org/10.1016/j.drudis.2019.05.033
Publication status	Published - Aug 2019
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2019 Elsevier Ltd

ASJC Scopus Subject Areas

Pharmacology
Drug Discovery

Access to Document

10.1016/j.drudis.2019.05.033

Cite this

@article{a4177a9149054876a1a9af94cd6ced30,

title = "Nitric oxide: a drug target for glaucoma revisited",

abstract = "A reduction in intraocular pressure (IOP) is the only recognized therapy for glaucoma. Hence, drugs exhibiting ocular hypotensive effects are important targets for antiglaucomatous drug development. IOP is determined by the equilibrium of aqueous humor production and outflow through either the trabecular meshwork or the uveoscleral outflow pathway. There is increasing evidence that nitric oxide (NO) has a major role in the regulation of IOP by directly acting on the trabecular meshwork and thereby lowering IOP. Taking advantage of this mechanism, newly designed NO-donating drugs combine the IOP-lowering effect of known substances with the trabecular meshwork outflow-increasing effect of NO. Here, we review the molecular mechanism of this new entity of IOP-lowering drugs.",

author = "Gerhard Garh{\"o}fer and Leopold Schmetterer",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier Ltd",

year = "2019",

month = aug,

doi = "10.1016/j.drudis.2019.05.033",

language = "English",

volume = "24",

pages = "1614--1620",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier Limited",

number = "8",

}

TY - JOUR

T1 - Nitric oxide

T2 - a drug target for glaucoma revisited

AU - Garhöfer, Gerhard

AU - Schmetterer, Leopold

PY - 2019/8

Y1 - 2019/8

N2 - A reduction in intraocular pressure (IOP) is the only recognized therapy for glaucoma. Hence, drugs exhibiting ocular hypotensive effects are important targets for antiglaucomatous drug development. IOP is determined by the equilibrium of aqueous humor production and outflow through either the trabecular meshwork or the uveoscleral outflow pathway. There is increasing evidence that nitric oxide (NO) has a major role in the regulation of IOP by directly acting on the trabecular meshwork and thereby lowering IOP. Taking advantage of this mechanism, newly designed NO-donating drugs combine the IOP-lowering effect of known substances with the trabecular meshwork outflow-increasing effect of NO. Here, we review the molecular mechanism of this new entity of IOP-lowering drugs.

AB - A reduction in intraocular pressure (IOP) is the only recognized therapy for glaucoma. Hence, drugs exhibiting ocular hypotensive effects are important targets for antiglaucomatous drug development. IOP is determined by the equilibrium of aqueous humor production and outflow through either the trabecular meshwork or the uveoscleral outflow pathway. There is increasing evidence that nitric oxide (NO) has a major role in the regulation of IOP by directly acting on the trabecular meshwork and thereby lowering IOP. Taking advantage of this mechanism, newly designed NO-donating drugs combine the IOP-lowering effect of known substances with the trabecular meshwork outflow-increasing effect of NO. Here, we review the molecular mechanism of this new entity of IOP-lowering drugs.

UR - http://www.scopus.com/inward/record.url?scp=85066943747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066943747&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2019.05.033

DO - 10.1016/j.drudis.2019.05.033

M3 - Review article

C2 - 31173910

AN - SCOPUS:85066943747

SN - 1359-6446

VL - 24

SP - 1614

EP - 1620

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 8

ER -

Nitric oxide: a drug target for glaucoma revisited

Abstract

Bibliographical note

ASJC Scopus Subject Areas

Access to Document

Other files and links

Fingerprint

Cite this